E

Evonik

Global specialty chemicals manufacturer and supplier

Business Development Manager - Personal Care

Full-TimeUpdated on 10/23/2026
$94.6k - $171.5k
Mid
Bachelor's, Master's
United States
In PersonField sales in the USA; candidates near Chicago, Dallas, or Los Angeles are preferred. Travel up to 20–40% as needed.
Sales & Account ManagementField Sales

About the job

Requirements
  • A bachelor's degree is required.
  • At least 3 years of experience in the personal care industry.
  • Strong knowledge of cosmetic ingredients, formulation processes, skin science, regulatory requirements, and product claims.
  • Ability to identify customer needs and develop value-driven product solutions.
  • Strong communication, presentation, sales, analytical, and relationship management skills.
  • Strong organizational skills and ability to manage multiple priorities.
  • Proficiency with Microsoft Suite and customer relationship management tools.
  • Ability to work collaboratively across global teams and travel up to 20–40% as needed.
Responsibilities
  • Perform regular sales calls and in-person visits to existing and potential customers to grow regional sales and profitability, and support project and opportunity pipeline development for selected cosmetic raw material segments.
  • Support marketing activities to promote segment products and serve as a sales specialist and technical sales contact during customer presentations; enter contact reports into the customer relationship management system according to business rules.
  • Manage opportunities for assigned segments and region, including monitoring, regular review and analysis, maintaining pipeline hygiene, and partnering with account managers to ensure pipeline quality and viability.
  • Contribute as a member of global and regional segment teams in developing and implementing global strategy, regional strategy, and action plans; provide regional market input for product and market development initiatives.
  • Develop regional segment strategy and lead its implementation by studying market trends, competitors and their product lines, and key customers in the segment.
  • Participate in trade shows, industry events, and associations to promote and advocate for the company's actives products, and represent the segment products throughout the industry.
  • Support customer interactions involving complaint management, regulatory requests, audits, customer projects, and other projects.
  • Provide account management support when required, including delivering timely customer feedback, conducting customer visits, preparing forecasts, managing pricing, and presenting products.
Desired Qualifications
  • A master's degree in Life Sciences, Cosmetic Science, Chemistry, Biology, or a related field is preferred.
  • Experience in business development, sales, marketing, or technical roles is preferred.
  • Experience with cosmetic formulation is preferred.

About the company

Evonik is a global specialty chemicals company that makes high-value ingredients used in everyday products, such as cars, footwear, and animal feed. Its products are designed to enhance performance by providing tailored chemical solutions across multiple industries and applications. Evonik operates in more than 100 countries, producing specialty chemicals through advanced formulations and manufacturing processes that meet specific customer needs. The company differentiates itself by its focused strategy on high-margin specialty chemicals after restructuring, its large, multinational manufacturing footprint, and ongoing efficiency-improvement efforts that paused major acquisitions through 2027 to prioritize internal transformation. The goal is to strengthen its leadership in specialty chemicals and sustain profitable growth by delivering specialized ingredients and performance materials while improving operational efficiency.

Company Size

10,001+

Company Stage

IPO

Headquarters

Essen, Germany

Founded

2007

Get referred to Evonik

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 EBITDA rose 24% to €630 million, and guidance increased to €2.2 billion.
  • Vancouver GMP and Indiana upgrades target 2029 demand in mRNA and APIs.
  • Pilot membrane manufacturing in June 2026 positions Evonik for green-hydrogen commercialization.

What critics are saying

  • Evonik is cutting 3,200 jobs through 2029, signaling stubborn structural cost pressure.
  • Witten closure provisions and Oxeno impairment show portfolio cleanup still hurts earnings.
  • Singapore methionine force majeure exposes Evonik to feedstock shocks and geopolitical shutdowns.

What makes Evonik unique

  • Evonik combines CDMO, lipids, and specialty ingredients across pharma, feed, and polymers.
  • Its Vancouver and Tippecanoe investments deepen high-switching-cost pharmaceutical manufacturing capabilities.
  • Evonik’s C4 and methionine platforms give it scale competitors like BASF lack.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Disability Insurance
  • Life Insurance
  • Parental Leave
  • Tuition Reimbursement
  • 401(k) Retirement Plan
  • Health Savings Account/Flexible Spending Account
  • Paid Vacation
  • Flexible Work Hours
  • Hybrid Work Options

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

8%
PR Newswire
Aug 27th, 2026
Evonik invests $109.5M in new lipid drug delivery facility in Vancouver

Evonik is investing over C$150 million (€93 million) in a new GMP manufacturing facility for lipid-based drug delivery in Vancouver, Canada. The Canadian federal government's Strategic Response Fund is supporting the project with up to C$68 million (around €42 million). The facility will more than triple Evonik's current production capacity for advanced pharmaceutical products, including vaccines and therapeutics. Drug product production is planned to begin at the end of 2029. The expansion builds on Evonik Vancouver Laboratories' expertise in lipid-based drug delivery since the 1990s. The site provides CDMO services for advanced LNP and liposomal delivery systems, from formulation research through GMP clinical trial manufacturing. The LNP market is projected to reach $2.7 billion by 2034, driven by growing demand for nucleic acid therapeutics.

Yahoo Finance
Aug 13th, 2026
Evonik's 24% Q2 EBITDA surge drives polymeric surfactants market to projected $17.8B by 2035

Evonik reported a 24% surge in Q2 EBITDA, while the global polymeric surfactants market is projected to reach $17.8 billion by 2035, according to a new report from ResearchAndMarkets.com. The market was valued at $10.5 billion in 2025 and is expected to grow at a 5.4% CAGR through 2035. Growth is driven by the transition towards water-based and low-VOC systems in coatings, paints, personal care, and industrial applications. Block copolymers held a 42.2% market share in 2025, making them the leading product category. Their dominance stems from precise molecular structure control and versatility across multiple applications including coatings, pharmaceuticals, agriculture, and personal care. The personal care and cosmetics industry represents a key growth area, fuelled by consumer demand for premium products offering improved texture and stability. Manufacturers are increasingly incorporating polymeric surfactants into product development as regulatory requirements and sustainability objectives evolve.

PR Newswire
Jul 8th, 2026
Evonik invests $100M to upgrade Indiana drug substance manufacturing facility

Evonik is investing $100 million over five years to modernise its drug substance manufacturing facility in Lafayette, Indiana. The investment will upgrade equipment including 100 m³ reactors, enhance automation, and improve efficiency at the site. The German chemicals company aims to meet growing demand for US-based contract development and manufacturing organisation services. The Tippecanoe facility is Evonik's second-largest US site and one of the world's largest active pharmaceutical ingredient facilities. The site features 170 m³ of high-potency API capacity, 860 m³ of reactor capacity for general APIs, and 2,500 m³ for large-scale fermentation. Evonik acquired the facility from Eli Lilly in 2010. The modernisation supports production of increasingly complex molecules for cancer, metabolic, and cardiovascular disease treatments whilst reducing greenhouse gas emissions.

AktienSensor
Jun 10th, 2026
Evonik shareholder raises $424M via convertible debt to fund R&D and bolster capital structure

Evonik Industries' principal shareholder, RAG-Stiftung, has issued €375 million in convertible debt maturing in December 2031. The note carries a 1.45% coupon and a conversion price of €19.46 per share, representing a 27% premium over the reference price at issuance. The transaction is part of RAG-Stiftung's long-term capital-raising framework, bringing its total outstanding convertible debt to approximately €1.4 billion. The low coupon reflects disciplined interest expense management in the specialty-chemicals sector. If converted, the debt would retire and dilute the foundation's equity stake by less than 1%. The proceeds will support research and development spending and provide a buffer against commodity price volatility. The German specialty-chemicals company faces competition from BASF, Lanxess and Solvay in high-performance polymers and advanced additives.

Yahoo Finance
Jun 10th, 2026
Evonik launches membrane to cut green hydrogen costs by 25%

German chemicals group Evonik has developed a membrane for electricity-based hydrogen production that could significantly reduce costs. Commercial manufacturing of the Anion Exchange Membrane (AEM) electrolysis system has begun at a pilot plant in Germany's Ruhr region. The technology uses fewer precious metals than traditional methods and allows hydrogen to be produced under pressure, eliminating additional compression steps. Specialist studies suggest the system could reduce investment costs by at least 25%. Green hydrogen currently costs two to four times more than grey hydrogen produced from natural gas. Evonik is targeting large-scale application in China, where it has established a technology centre in Shanghai to test the membranes under industrial conditions with local partners. The company expects strong demand growth for green hydrogen as industries transition to carbon neutrality.